Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15200265 | 1.00 | OPRM1 (0.48) | OPRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15580639 | 1.00 | OPRM1 (0.48) | OPRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22276366 | 0.91 | EPHX1 (0.58) | OPRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1678458 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL28988641 | 0.87 | — | — | |
| SCHEMBL23221254 | 0.84 | OPRM1 (0.43) | OPRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6884666 | 0.84 | PLG (0.53) | OPRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21728758 | 0.84 | OPRM1 (0.43) | OPRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18179835 | 0.84 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL22697173 | 0.82 | OPRM1 (0.42) | OPRM1CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | disclosed |
| EP-3154997-B9 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3753578-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| US-20140336373-A1 | NOVEL COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2014-11-13 | — | — | US | disclosed |
| US-8178704-B2 | For analyzing seven transmembrane domain receptors coupled to phospholipase C and receptors having tyrosine kinase activity; kits; monoclonal/polyclonal antibodies | CIS BIO INTERNATIONAL (FR) | 2012-05-15 | — | — | US | disclosed |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | KOWA COMPANY, LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110236952-A1 | NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF | CIS BIO INTERNATIONAL (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110236952-A1 | NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF | CIS BIO INTERNATIONAL (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20100204467-A1 | LANTHANIDE (III) ION COMPLEXING COMPOUNDS, LUMINESCENT LANTHANIDE (III) ION COMPLEXES AND USE THEREOF AS FLUORESCENT LABELS | CIS BIO INTERNATIONAL (FR) | 2010-08-12 | — | — | US | disclosed |
| US-20100143960-A1 | CYANINE DERIVATIVES, FLUORESCENT CONJUGATES CONTAINING SAME AND USE THEREOF | CIS BIO INTERNATIONAL (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100143960-A1 | CYANINE DERIVATIVES, FLUORESCENT CONJUGATES CONTAINING SAME AND USE THEREOF | CIS BIO INTERNATIONAL (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20080261237-A1 | Inositol-Phosphate Derivatives and Method of Detecting Inositol-1-Phosphate | CIS BIO INTERNATIONAL (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080261237-A1 | Inositol-Phosphate Derivatives and Method of Detecting Inositol-1-Phosphate | CIS BIO INTERNATIONAL (FR) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236952-A1 | NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF | OGG1, UNG, MPG | OPRM1 1571/4885CYP1A2 631/4885CYP2D6 190/4885 |
| US-20080261237-A1 | Inositol-Phosphate Derivatives and Method of Detecting Inositol-1-Phosphate | IPMK, PLCG1, IP6K1 | OPRM1 850/4885CYP1A2 4447/4885CYP2D6 3919/4885 |
| US-20100204467-A1 | LANTHANIDE (III) ION COMPLEXING COMPOUNDS, LUMINESCENT LANTHANIDE (III) ION COMPLEXES AND USE THEREOF AS FLUORESCENT LABELS | CBR3, CLIC4, GLRA3 | OPRM1 429/4885CYP1A2 2359/4885CYP2D6 1894/4885 |
| US-20140336373-A1 | NOVEL COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | RCC1, RCC2, C1R | OPRM1 4036/4885CYP1A2 2202/4885CYP2D6 3230/4885 |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | ACSL6, ACSL3, ACSL1 | OPRM1 1242/4885CYP1A2 330/4885CYP2D6 64/4885 |
| US-20100143960-A1 | CYANINE DERIVATIVES, FLUORESCENT CONJUGATES CONTAINING SAME AND USE THEREOF | C9, CBR3, C3AR1 | OPRM1 418/4885CYP1A2 1768/4885CYP2D6 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.